A venture capital insider trimming a 6-year-old position is a routine portfolio action, not a negative signal on the company's prospects. However, watch for actual execution of these sales on August 14 or shortly thereafter — if all shares are sold, it will increase float slightly. No immediate catalyst change; continue monitoring upcoming clinical data readouts which are the primary drivers for this biotech.
Price Chart
Executive Summary
Atlas Venture, a founding investor in Dyne Therapeutics, filed multiple Form 144 notices on August 14, 2026, signaling intent to sell a combined 322,465 shares of DYN common stock worth approximately $8.4 million. The filing covers two Atlas entities (Opportunity Fund I, L.P. and Fund XI, L.P.) and represents an early-stage venture capital exit. While the dollar amount is modest relative to Dyne's $4.8B market cap, the coordinated sale by a key insider at a time of strong analyst consensus (90% buy/overweight) may signal portfolio rebalancing rather than fundamental concern.
Key Facts
- Atlas Venture Opportunity Fund I, L.P. filed Form 144 for 322,465 shares on August 14, 2026.
- Atlas Venture Fund XI, L.P. also filed Form 144 on the same date for shares of Dyne Therapeutics.
- The estimated aggregate value of the proposed sale is approximately $8.37 million based on a $25.96 reference price.
- Shares were acquired in a private placement on August 7, 2020 — a ~6-year hold period.
- The filing lists Merrill Lynch as the broker for the proposed sale.
Financial Impact
Atlas Venture proposes to sell up to 322,465 shares valued at ~$8.37M, representing roughly 0.17% of DYN's $4.8B market cap.
Risk Factors
- Insider selling, even by VCs, can create short-term overhang if the market misinterprets it as a lack of confidence.
- Additional unregistered selling by other early investors could follow, increasing supply.
- The company's success depends on pipeline execution in muscle disease therapies; any clinical setback could accelerate insider selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (DYN) — Batch item 1 | 0001628280-26-057191 |
| Document: 0001628280-26-057191-index.html | 0001628280-26-057190 |
| Document: 0001628280-26-057191.txt | 0001628280-26-057191 |
| 144 Filing (DYN) — Batch item 4 | 0001628280-26-057190 |
| Document: 0001628280-26-057190-index.html | 0001628280-26-057191 |
| 144 Filing (DYN) — Batch item 6 | 0001628280-26-057191 |
| 144 Filing (DYN) — Batch item 7 | 0001628280-26-057190 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.39 (+41.15%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.39 (−41.15%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.39 (+40.12%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.39 (−40.12%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.39 (−40.12%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.39 (−40.19%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.39 (+33.69%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.39 (−34.37%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.39 (−29.37%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.39 (+30.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access